307
|
Gillanders E, Hank Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN, Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73:301-13. [PMID: 12844286 PMCID: PMC1180369 DOI: 10.1086/377140] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2003] [Accepted: 05/20/2003] [Indexed: 11/03/2022] Open
Abstract
Over the past 20 years, the incidence of cutaneous malignant melanoma (CMM) has increased dramatically worldwide. A positive family history of the disease is among the most established risk factors for CMM; it is estimated that 10% of CMM cases result from an inherited predisposition. Although mutations in two genes, CDKN2A and CDK4, have been shown to confer an increased risk of CMM, they account for only 20%-25% of families with multiple cases of CMM. Therefore, to localize additional loci involved in melanoma susceptibility, we have performed a genomewide scan for linkage in 49 Australian pedigrees containing at least three CMM cases, in which CDKN2A and CDK4 involvement has been excluded. The highest two-point parametric LOD score (1.82; recombination fraction [theta] 0.2) was obtained at D1S2726, which maps to the short arm of chromosome 1 (1p22). A parametric LOD score of 4.65 (theta=0) and a nonparametric LOD score of 4.19 were found at D1S2779 in nine families selected for early age at onset. Additional typing yielded seven adjacent markers with LOD scores >3 in this subset, with the highest parametric LOD score, 4.95 (theta=0) (nonparametric LOD score 5.37), at D1S2776. Analysis of 33 additional multiplex families with CMM from several continents provided further evidence for linkage to the 1p22 region, again strongest in families with the earliest mean age at diagnosis. A nonparametric ordered sequential analysis was used, based on the average age at diagnosis in each family. The highest LOD score, 6.43, was obtained at D1S2779 and occurred when the 15 families with the earliest ages at onset were included. These data provide significant evidence of a novel susceptibility gene for CMM located within chromosome band 1p22.
Collapse
Affiliation(s)
- Elizabeth Gillanders
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Suh-Hang Hank Juo
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Elizabeth A. Holland
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - MaryPat Jones
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Derek Nancarrow
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Diana Freas-Lutz
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Raman Sood
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Naeun Park
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Mezbah Faruque
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Carol Markey
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Richard F. Kefford
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Jane Palmer
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Wilma Bergman
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - D. Timothy Bishop
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Margaret A. Tucker
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Brigitte Bressac-de Paillerets
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Johan Hansson
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - The Lund Melanoma Study Group
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Mitchell Stark
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Nelleke Gruis
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Julia Newton Bishop
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Alisa M. Goldstein
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Joan E. Bailey-Wilson
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Graham J. Mann
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Nicholas Hayward
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | - Jeffrey Trent
- Cancer Genetics Branch, National Human Genome Research Institute, and Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda; Columbia Genome Center and Department of Epidemiology, Columbia University, New York; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney; Queensland Cancer Fund Research Unit, Brisbane, Australia; Department of Dermatology and Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands; Genetic Epidemiology Division, Cancer Research UK Clinical Centre, Leeds, United Kingdom; Institut Gustave Rousy, Villejuif, France; Department of Oncology-Pathology, Karolinska Hospital, Stockholm; Lund Cancer Center Department of Oncology, University Hospital, Lund, Sweden; Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore; and Translational Genomics Research Institute, Phoenix
| | | |
Collapse
|